BCT and BCTXZ Related Headlines
Go Back- BriaCell Therapeutics Announces Pricing of Offering
- BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
- BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
- BriaCell adds Penn Medicine cancer center to phase 3 breast cancer trial
- BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
- BriaCell enrolls over 230 patients in phase 3 breast cancer study
- BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
- BriaCell adds NYU cancer center to phase 3 breast cancer trial
- BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
- BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
- BriaCell Announces Six Clinical Data Presentations at ASCO 2026
- BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models
- BriaCell presents cancer therapy data at 2026 AACR meeting
- BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
- BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
- BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
- BriaCell reports extended survival in metastatic breast cancer trial
- BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
- BriaCell completes $30 million public offering of units
- BriaCell Therapeutics Announces Closing of US$30 million Public Offering
- BriaCell prices $30 million public offering at $5.59 per unit
- BriaCell Therapeutics Announces Pricing of $30 million Public Offering
- BriaCell presents phase 2 survival and phase 3 data at breast cancer symposium
- BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
- BriaCell to present clinical trial data at breast cancer symposium
- BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025
- BriaCell to present clinical data at breast cancer symposium
- BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025
- BriaCell to present clinical data at breast cancer symposium
- BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025
- BriaCell receives fourth positive safety board recommendation for phase 3 study
- BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
- BriaCell expands Phase 3 breast cancer study to 79 clinical sites
- BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study
- BriaCell partners with MSK accelerator for breast cancer therapy
- BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer
- BriaCell presents Phase 3 biomarker data at ESMO conference
- BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025
- BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting
- BriaCell study validates Bria-OTS+ cancer therapy mechanism
- BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal
- BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer
- BriaCell sets August 25 as effective date for 1-for-10 share consolidation
- BriaCell Announces Proposed Effective Date of Share Consolidation
- BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer
- BriaCell Announces Proposed Effective Date of Share Consolidation
- BriaCell adds UCLA Health to phase 3 breast cancer trial
- BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study
- BriaCell receives New Zealand patent for whole cell cancer technology
- BriaCell Awarded New Zealand Patent for its Whole Cell Technology
- BriaPro files patent for cancer immunotherapy platform
- BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents
- BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer
- BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer
- BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven
- BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer
BCT and BCTXZ Related Press Releases
Go Back- BriaCell Therapeutics Announces Pricing of Offering
- BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™
- BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer
- BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
- BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients
- BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
- BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer
- BriaCell Announces Six Clinical Data Presentations at ASCO 2026
- BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models
- BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting
- BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License
- BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting
- BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients
- BriaCell Therapeutics Announces Closing of US$30 million Public Offering
- BriaCell Therapeutics Announces Pricing of $30 million Public Offering
- BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025
- BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025
- BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025
- BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025
- BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer
- BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study
- BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer
- BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025
- BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting
- BriaCell’s Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal
- BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer
- BriaCell Announces Proposed Effective Date of Share Consolidation
- BriaCell Selected for MSK’s 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer
- BriaCell Announces Proposed Effective Date of Share Consolidation
- BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study
- BriaCell Awarded New Zealand Patent for its Whole Cell Technology
- BriaCell’s Subsidiary, BriaPro, Files Patent Application for Immuno-Oncology Platform with Novel Multitargeting Agents
- BriaCell’s Bria-IMT™ Demonstrates Survival Advantage over Trodelvy® and Control Group in Metastatic Breast Cancer
- BriaCell Phase 2 Survival Achievement: 52% of Patients Surpass One-Year Milestone in Metastatic Breast Cancer
- BriaCell Highlights Additional Phase 3 Clinical Sites Including Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven
- BriaCell Announces Positive Recommendation from Data Safety Monitoring Board for Pivotal Phase 3 Study in Metastatic Breast Cancer
